Divergent Hypoglycemic Effects of Hepatic-Directed Prandial Insulin: A 6-Month Phase 2b Study in Type 1 Diabetes

Latest Updates

News

OPTI-2 at EASD 2026: HDV-Insulin Lispro Reduces Hypoglycemia Risk in Adults with Type 1 Diabetes

https://vimeo.com/1243093783/329c6b2ec8

Ira Pastor, host of Progress, Potential and Possibilities, interviews Robert Geho

https://youtu.be/jx6ZfxpO3ps?si=NtYi4uLkwG--Feua

GEN: Diasome’s HDV-Insulin for T1D Finalizing Phase III Plans After Promising Data

https://www.genengnews.com/topics/translational-medicine/diasomes-hdv-insulin-for-t1d-finalizing-phase-iii-plans-after-promising-data/

Diasome Pharmaceuticals to Present HDV-Insulin Phase 2b Clinical Data at EASD 2026 and Inaugural Breakthrough T1D Clinical & Research Congress